Tianjin Development (00882): Tianjin Lisheng Pharmaceutical Reports 3.71 Billion Yuan Net Profit for the First Three Quarters, Up 119.05% Year-on-Year

Stock News

10/24

According to an announcement from Tianjin Development (00882), its indirectly held subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical), reported total operating revenue of 1.007 billion yuan for the nine months ending September 30, 2025, a year-on-year decrease of 1.61%. The net profit attributable to shareholders of the parent company was 371 million yuan, marking a significant year-on-year increase of 119.05%. The basic earnings per share amounted to 1.44 yuan.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1106698407"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106698407\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106698407?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 06:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106698407","market":"hk","top_or_hot":-1,"title":"Tianjin Development (00882): Tianjin Lisheng Pharmaceutical Reports 3.71 Billion Yuan Net Profit for the First Three Quarters, Up 119.05% Year-on-Year","media":"Stock News","content":"<p>According to an announcement from Tianjin Development (00882), its indirectly held subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical), reported total operating revenue of 1.007 billion yuan for the nine months ending September 30, 2025, a year-on-year decrease of 1.61%. The net profit attributable to shareholders of the parent company was 371 million yuan, marking a significant year-on-year increase of 119.05%. The basic earnings per share amounted to 1.44 yuan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin Development (00882): Tianjin Lisheng Pharmaceutical Reports 3.71 Billion Yuan Net Profit for the First Three Quarters, Up 119.05% Year-on-Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin Development (00882): Tianjin Lisheng Pharmaceutical Reports 3.71 Billion Yuan Net Profit for the First Three Quarters, Up 119.05% Year-on-Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-24 06:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to an announcement from Tianjin Development (00882), its indirectly held subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical), reported total operating revenue of 1.007 billion yuan for the nine months ending September 30, 2025, a year-on-year decrease of 1.61%. The net profit attributable to shareholders of the parent company was 371 million yuan, marking a significant year-on-year increase of 119.05%. The basic earnings per share amounted to 1.44 yuan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002393","symbol_name":"力生制药","start_time":0,"source_url":"","article_id":"1106698407","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106698407","pubTimestamp":1761257889,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to an announcement from Tianjin Development (00882), its indirectly held subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical), reported total operating revenue of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"002393":"力生制药","BK0028":"国家队","00882":"天津发展","BK0239":"医药制造","BK1232":"复合型公用事业","BK0188":"融资融券"},"translate_title":"天津发展(00882)：天津力生制药报前三季净利37.1亿元同比增119.05%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002393":1,"00882":1},"content_text":"According to an announcement from Tianjin Development (00882), its indirectly held subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical), reported total operating revenue of 1.007 billion yuan for the nine months ending September 30, 2025, a year-on-year decrease of 1.61%. The net profit attributable to shareholders of the parent company was 371 million yuan, marking a significant year-on-year increase of 119.05%. The basic earnings per share amounted to 1.44 yuan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}